AOTI Incis a prominent constituent of the FTSE 100 index, listed on the London Stock Exchange under the ticker LSE:AOTI. With a market capitalisation of approximately 30.31M GBP, the company stands as one of the most significant players in the Healthcare sector, specifically within …
As of early 2026, Allergy Therapeutics Plc shares trade at approximately 9.9 GBX on the LSE. The stock carries a price-to-earnings ratio of a level that reflects the company current earnings dynamics, with earnings per share on a diluted basis at N/A USD over …
Shares of Genus plc are gaining around 4% on 1 April 2026 as investors rotate into defensive growth stocks within the FTSE 250, particularly those exposed to global food security, agricultural biotechnology, and resilient demand cycles. The Genus stock price movement aligns with broader …
Allergy Therapeutics Plc(LSE:AGY) fell 5.34% on April 1, 2026, amid biotech market volatility and broader risk-off sentiment in small- and mid-cap healthcare stocks.
Fusion Antibodies PLC(LSE:FAB) fell 4.00% on April 1, 2026, reflecting ongoing pressure on small-cap biotech stocks.
The decline in ConvaTec Group plc (LSE:CTEC) shares reflects a combination of macroeconomic headwinds, sector rotation, and cautious investor sentiment rather than any single negative company-specific trigger.
Smith & Nephew (LSE:SN.) shares declined around 1.3% on 31 March 2026, reflecting a mix of global macro uncertainty, healthcare sector rotation, and company-specific growth concerns. Despite being a defensive healthcare stock, the current environment is shifting investor preference toward higher-yield assets and energy-linked …
Syncona share price decline of around 2.9% on 31 March 2026 reflects a mix of global macroeconomic pressure, biotech sector-specific weakness, and ongoing geopolitical uncertainty. As a life sciences investment firm heavily exposed to early-stage biotech companies, Syncona is particularly sensitive to shifts in …
EKF Diagnostics Holdings plcis a UK-based medical diagnostics company providing point-of-care testing solutions and diagnostic instrumentation to healthcare providers globally. The company focuses on technologies that enable rapid and accurate clinical testing, including blood analysis and biomarker detection across diabetes management, anemia screening, and …
SkinBioTherapeutics Plcis a UK-based biotechnology company focused on developing microbiome-derived technologies to improve skin health. Listed on the AIM market, the company’s core platform, SkinBiotix®, is designed to strengthen the skin barrier, support repair, and reduce susceptibility to infection. In addition, its AxisBiotix programme …